Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2025)

Puma Biotechnology's Long-Term Deferred Tax history spans 2 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 45.87% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, down 45.87%, while the annual FY2025 figure was $3.8 million, 45.87% down from the prior year.
  • Long-Term Deferred Tax reached $3.8 million in Q4 2025 per PBYI's latest filing, down from $7.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $7.1 million in Q4 2024 to a low of $3.8 million in Q4 2025.